Alissa Cooper
Physician · Mass General Brigham
Credentials: · · · ·
History
- 2025–Present
- 2020–2022
2013–2017
Research
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Review · Nature Reviews Clinical Oncology · 2022 · First of 3 authors · 447 citations
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Cancer Discovery · 2023 · Co-first of 66 authors · 174 citations
Circulation Heart Failure · 2019 · 153 citations
9 papers
- NR
9 papers
- MA
8 papers
7 papers · 7 as a resident
- AS
6 papers
- BC
6 papers
6 papers
- JG
6 papers
Clinical trials
- 2026–2028
A Study of CS231295 in Patients With Advanced Solid Tumors
Site PI · Not yet recruiting · Phase 1
ThalassaX Therapeutics United States Ltd